American Association for Cancer Research
Browse
00085472can163292-sup-175588_2_unknown_upload_3948956_gnl1n5.pptx (270.33 kB)

Supplementary Figure 7 from Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas

Download (270.33 kB)
figure
posted on 2023-03-31, 00:44 authored by Anushka Dongre, Mohammad Rashidian, Ferenc Reinhardt, Aaron Bagnato, Zuzana Keckesova, Hidde L. Ploegh, Robert A. Weinberg

Supplementary Figure 7 shows Epithelial and Mesenchymal cells in mixed tumors before and after immunotherapy

Funding

NIH

Cancer Research Foundation

Samuel Waxman Cancer Research Foundation

Ludwig Center for Molecular Oncology

Lustgarten Foundation

Ludwig Fund for Cancer Research

Cancer Research Institute

History

ARTICLE ABSTRACT

The epithelial-to-mesenchymal transition (EMT) is a cell biological program that confers mesenchymal traits on carcinoma cells and drives their metastatic dissemination. It is unclear, however, whether the activation of EMT in carcinoma cells can change their susceptibility to immune attack. We demonstrate here that mammary tumor cells arising from more epithelial carcinoma cell lines expressed high levels of MHC-I, low levels of PD-L1, and contained within their stroma CD8+ T cells and M1 (antitumor) macrophages. In contrast, tumors arising from more mesenchymal carcinoma cell lines exhibiting EMT markers expressed low levels of MHC-I, high levels of PD-L1, and contained within their stroma regulatory T cells, M2 (protumor) macrophages, and exhausted CD8+ T cells. Moreover, the more mesenchymal carcinoma cells within a tumor retained the ability to protect their more epithelial counterparts from immune attack. Finally, epithelial tumors were more susceptible to elimination by immunotherapy than corresponding mesenchymal tumors. Our results identify immune cells and immunomodulatory markers that can be potentially targeted to enhance the susceptibility of immunosuppressive tumors to various therapeutic regimens. Cancer Res; 77(15); 3982–9. ©2017 AACR.

Usage metrics

    Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC